For patients with moderate-to-severe Crohn disease, upadacitinib induction and maintenance treatment are superior to placebo, according to a study published in the May 25 issue of the New England Journal of Medicine.
May 31, 2023
0
6
Upadacinib is a new drug for the treatment of adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy. In an early benefit assessment, the German Institute ...
Dec 9, 2021
0
4
For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine.
Apr 1, 2021
0
3
(HealthDay)—Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDS), according to a study published online Oct. 15 in the New England ...
Oct 16, 2020
0
0
In a clinical trial of patients with rheumatoid arthritis, treatment with a drug called upadacitinib provided greater benefits than methotrexate, the most commonly used initial therapy for rheumatoid arthritis.
Jul 8, 2020
0
3
In a large-scale, international study led by renowned rheumatologist Josef Smolen from the Department of Medicine III, a still-to-be-approved drug containing the selective janus kinase inhibitor upadacitinib has proved itself ...
Jun 6, 2019
0
134
